Can anifrolumab calm the painful boils of HS? a new trial seeks answers.
NCT ID NCT06374212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether anifrolumab, an antibody drug, can reduce skin abscesses and nodules in people with hidradenitis suppurativa (HS). Fifteen adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks. The main goal is to see if at least half of participants achieve a 50% reduction in inflammatory lesions by week 12, while also monitoring safety and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516, United States